All Stories

  1. Understanding the Key Determinants of Cardiovascular and Metabolic Disease Progression to Develop Effective Therapeutic Strategies
  2. The siRNA-mediated knockdown of AP-1 restores the function of the pulmonary artery and the right ventricle by reducing perivascular and interstitial fibrosis and key molecular players in cardiopulmonary disease
  3. The Effects of Sirna-mediated Knockdown of Ap-1 on Pulmonary Arterial and Right Ventricular Dysfunction Associated With Cardiac and Pulmonary Fibrosis in Cardiopulmonary Disease
  4. Microvesicle-associated and circulating microRNAs in diabetic dyslipidemia: miR-218, miR-132, miR-143, and miR-21, miR-122, miR-155 have biomarker potential
  5. Progress in Biomaterials for Cardiac Tissue Engineering and Regeneration
  6. Cardiovascular Disease as a Consequence or a Cause of Cancer: Potential Role of Extracellular Vesicles
  7. Stem cell‐derived extracellular vesicles reduce the expression of molecules involved in cardiac hypertrophy—In a model of human-induced pluripotent stem cell-derived cardiomyocytes
  8. Microvesicles and Microvesicle-Associated microRNAs Reflect Glioblastoma Regression: Microvesicle-Associated miR-625-5p Has Biomarker Potential
  9. Inflammation-induced arterial dysfunction in atherosclerosis; the modulating action of mesenchymal stem cell-derived extracellular vesicles
  10. MicroRNAs in circulating microvesicles and plasma as biomarkers that complement the clinical diagnosis of diabetic dyslipidemia and its complications
  11. VLA4-Enhanced Allogeneic Endothelial Progenitor Cell-Based Therapy Preserves the Aortic Valve Function in a Mouse Model of Dyslipidemia and Diabetes
  12. Therapeutic Potential of Stem Cell-Derived Extracellular Vesicles on Atherosclerosis-Induced Vascular Dysfunction and Its Key Molecular Players
  13. The Multifaceted Role of Extracellular Vesicles in Glioblastoma: microRNA Nanocarriers for Disease Progression and Gene Therapy
  14. Extracellular vesicles—incorporated microRNA signature as biomarker and diagnosis of prediabetes state and its complications
  15. Extracellular Vesicles: Versatile Nanomediators, Potential Biomarkers and Therapeutic Agents in Atherosclerosis and COVID-19-Related Thrombosis
  16. Extracellular Vesicles from Adipose Tissue Stem Cells in Diabetes and Associated Cardiovascular Disease; Pathobiological Impact and Therapeutic Potential
  17. Part One: Extracellular Vesicles as Valuable Players in Diabetic Cardiovascular Diseases
  18. Part Two: Extracellular Vesicles as a Risk Factor in Neurodegenerative Diseases
  19. Intravenous Administration of Allogenic Cell-Derived Microvesicles of Healthy Origins Defends Against Atherosclerotic Cardiovascular Disease Development by a Direct Action on Endothelial Progenitor Cells
  20. Integrins α4β1 and αVβ3 are Reduced in Endothelial Progenitor Cells from Diabetic Dyslipidemic Mice and May Represent New Targets for Therapy in Aortic Valve Disease
  21. Hypertension Associated With Hyperlipidemia Induced Different MicroRNA Expression Profiles in Plasma, Platelets, and Platelet-Derived Microvesicles; Effects of Endothelial Progenitor Cell Therapy
  22. Diabetes-induced early molecular and functional changes in aortic heart valves in a murine model of atherosclerosis
  23. Early Diabetes Induces Alterations In Endothelial Progenitor Cell Phenotype And Homing In Mice Susceptible To Atherosclerosis
  24. Platelets of Healthy Origins Promote Functional Improvement of Atherosclerotic Endothelial Progenitor Cells
  25. Sera of Obese Type 2 Diabetic Patients Undergoing Metabolic Surgery Instead of Conventional Treatment Exert Beneficial Effects on Beta Cell Survival and Function: Results of a Randomized Clinical Study
  26. The Distinct Effects of Palmitic and Oleic Acid on Pancreatic Beta Cell Function: The Elucidation of Associated Mechanisms and Effector Molecules
  27. Circulating ectosomes: Determination of angiogenic microRNAs in type 2 diabetes
  28. Understanding the functional role of microRNA-214-3p in atherosclerosis for the identification of novel targeted therapies to prevent or reverse endothelial cell dysfunction and stimulate autophagy
  29. Endothelial progenitor cells - derived microparticles reproduce the favorable role of their parent cells of healthy origins in the treatment of atherosclerosis via microrna transfer
  30. Role of microparticles as microrna messengers in reestablishing of atherosclerosis-associated endothelial progenitor cell dysfunction
  31. Microparticles of healthy origins improve endothelial progenitor cell dysfunction via microRNA transfer in an atherosclerotic hamster model
  32. Endothelial Progenitor Cell Dysfunction in the Pathogenesis of Vascular Complications of Diabetes
  33. Microparticles: From Biogenesis to Biomarkers and Diagnostic Tools in Cardiovascular Disease
  34. Role of MicroRNA in Endothelial Dysfunction and Hypertension
  35. Effects of transplanted circulating endothelial progenitor cells and platelet microparticles in atherosclerosis development
  36. Vascular complications in diabetes: Microparticles and microparticle associated microRNAs as active players
  37. Midkine proteins in cardio-vascular disease.
  38. Lack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke
  39. Interaction of platelets with endothelial progenitor cells in the experimental atherosclerosis: Role of transplanted endothelial progenitor cells and platelet microparticles
  40. Microparticles and endothelial progenitor cells: a critical ratio in vascular atherosclerosis
  41. Activation profile of dorsal root ganglia Iba-1 (+) macrophages varies with the type of lesion in rats
  42. Irbesartan administration therapeutically influences circulating endothelial progenitor cell and microparticle mobilization by involvement of pro-inflammatory cytokines
  43. Circulating Endothelial Progenitor Cell and Platelet Microparticle Impact on Platelet Activation in Hypertension Associated with Hypercholesterolemia
  44. Collagen—Dexamethasone and Collagen-D3Scaffolds for Bone Tissue Engineering
  45. Circulating microparticles and endothelial progenitor cells in atherosclerosis: pharmacological effects of irbesartan
  46. Platelet dysfunction in vascular pathologies and how can it be treated
  47. The promise of EPC-based therapies on vascular dysfunction in diabetes
  48. Enoxaparin reduces adrenergic contraction of resistance arterioles in aging and in aging associated with diabetes via engagement of MAP kinase pathway
  49. Dysfunction of human subcutaneous fat arterioles in obesity alone or obesity associated with Type 2 diabetes
  50. Vascular dysfunction in diabetes: The endothelial progenitor cells as new therapeutic strategy
  51. Integration Properties of Wharton’s Jelly-derived Novel Mesenchymal Stem Cells into Ventricular Slices of Murine Hearts
  52. Platelet activation in hypertension associated with hypercholesterolemia: effects of irbesartan
  53. Intraplatelet Oxidative/Nitrative Stress: Inductors, Consequences, and Control
  54. MS357 IRBESARTAN REDUCES PLATELET ACTIVATION IN HYPERTENSIVE-HYPERCHOLESTEROLEMIC HAMSTER
  55. W55 RATIO OF MICROPARTICLES TO ENDOTHELIAL PROGENITOR CELLS, A MARKER OF VASCULAR DYSFUNCTION INDUCED BY COMBINED HYPERTENSION AND HYPERCHOLESTEROLEMIA; IRBERSARTAN EFFECT
  56. Increased Vitreous Microparticles in Diabetic Retinopathy
  57. Long-term high glucose concentration influences Akt, ERK1/2, and PTP1B protein expression in human aortic smooth muscle cells
  58. Chronic venous insufficiency is associated with elevated level of circulating microparticles
  59. Nebivolol Induces a Hyperpolarizing Effect on Smooth Muscle Cells in the Mouse Renal Artery by Activation of Beta-2-Adrenoceptors
  60. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension
  61. LB-PO-856 STRUCTURAL AND FUNCTIONAL ASSESSMENT OF SMALL ARTERIES IN OBESITY AND TYPE 2 DIABETES
  62. Effect of gap junction uncoupler heptanol on resistance arteries reactivity in experimental models of diabetes, hyperlipemia and hyperlipemia-diabetes
  63. Detection of DNA-bound advanced glycation end-products by immunoaffinity chromatography coupled to HPLC-diode array detection
  64. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery
  65. Double transgenic mice with Type 1 diabetes mellitus develop somatic, metabolic and vascular disorders
  66. Superoxide dismutase entrapped-liposomes restore the impaired endothelium-dependent relaxation of resistance arteries in experimental diabetes
  67. The contractile response of the mesenteric resistance arteries to prostaglandin F2α; effects of simultaneous hyperlipemia-diabetes
  68. Enoxaparin—a low molecular weight heparin, restores the altered vascular reactivity of resistance arteries in aged and aged–diabetic hamsters
  69. Beneficial effects of L -arginine supplementation in experimental hyperlipemia-hyperglycemia in the hamster
  70. Mechanisms of decreased bradykinin- induced vasodilation in experimental hyperlipemia-hyperglycemia: contribution of nitric oxide and Ca2+-activated K+ channels
  71. Age-dependent accumulation of advanced glycation endproducts is accelerated in combined hyperlipidemia and hyperglycemia, a process attenuated by L-arginine